The FDA accepted Avadel Pharmaceuticals’ marketing application for a daily sodium oxybate treatment, FT218, for excessive daytime sleepiness and cataplexy in adults with narcolepsy, the company said.
England saw a nearly 4% uptick in new antidepressant prescriptions during the COVID-19 pandemic. (The Lancet Psychiatry)
Diversity, equity, and inclusion leaders in academic medicine often don’t have the resources they need to implement change, according to a new “guideline for success” in the American Journal of Psychiatry.
Luvadaxistat, an investigational treatment for negative symptoms of schizophrenia, failed in a phase II trial. (BioPharmaDive)
But in other trial news, an accelerated 5-day course of intermittent theta-burst stimulation with Nexstim’s Navigated Brain Therapy device succeeded in reducing symptoms of severe depression, the maker announced.
Selective serotonin reuptake inhibitors weren’t tied to an increased risk of intracerebral hemorrhage, according to a study presented at the virtual American Academy of Neurology annual meeting. Catch up on more news from the meeting here.
Using machine learning, researchers pinpointed certain characteristics of “high utilizers” of inpatient psychiatric hospital services, including having dropped out of high school, diagnosis of schizophrenia, or being diagnosed with a co-occurring personality disorder. (The Journal of Health Care for the Poor and Underserved)
TikTok’s guide to managing physical anxiety? (Cosmopolitan)
Source: MedicalNewsToday.com
